The purpose of this pilot study is to assess the feasibility of longitudinal neurodevelopmental evaluation of fetuses and infants exposed to Lyme disease in utero. Participants with Lyme disease or Post-Treatment Lyme Disease Syndrome (PTLDS) will be recruited during pregnancy. Pregnancies will be monitored and infant development will be assessed from birth until age 18 months.
English speaker
Currently reside in the United States or Canada
Meet CDC criteria for: (1) clinical and/or laboratory diagnosis of Lyme disease during any stage of current pregnancy, OR (2) clinical diagnosis of PTLDS/Chronic Lyme within 3 years of current pregnancy
Able to be contacted for follow-up
Intellectually unable to comprehend study procedures
Health issues or metallic implant that precludes undergoing MRI
Incapable of completing study requirements (note: inability to travel to Children's National for in-person follow-up [for example, due to bedrest, travel restrictions, or financial inability to travel] is NOT an exclusion criterion; any interested and eligible participants requiring "remote only" participation will be permitted to join the study and complete all requirements besides in-person follow-up)
Pregnant participants with confirmed Borrelia burgdorferi infection or diagnosed PTLDS/Chronic Lyme will be enrolled during any trimester of pregnancy. All live-born infants will be followed to age 18 months and included in the study regardless of birth outcomes.
Cohort
Prospective
Neurodevelopmental assessments and follow-up
Other interventionAll infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
Number of parent-infant dyads enrolled in the study through completion of their infant's 18-month follow-up visit
The primary outcome of this pilot study is to assess the feasibility of enrollment and longitudinal follow-up of Lyme-exposed dyads. Investigators will measure the number of parent-infant dyads who are eligible for participation, who participate in each study visit, and who successfully complete the study through infant age 18 months, throughout the duration of the study.
Warner Initial Developmental Evaluation (WIDEA)
Infants will be evaluated at 2, 6, 12, and 18 months of age using the Warner Initial Developmental Evaluation (WIDEA). The WIDEA is a 43-item questionnaire to assess the functional domains of self-care, motor function, communication, and social cognition in young children.
Ages and Stages Questionnaire (ASQ)
Infants will be evaluated at 2, 6, 12, and 18 months of age using the Ages and Stages Questionnaire (ASQ). The ASQ will assess for possible developmental delays in the domains of communication, gross motor, fine motor, problem solving, and personal adaptive skills.
Alberta Infant Motor Scale (AIMS)
Infants will be evaluated at 2, 6, 12, and 18 months of age using the Alberta Infant Motor Scale (AIMS). The AIMS is an observational motor assessment that can be done in-person or using telehealth.
Infant height
Infants' height in centimeters will be collected at each study visit.
Click on the lead sponsor to view all of their trials.
Children's National Research Institute
Lead sponsor
Clinical Trials Network for Lyme and Other Tick-Borne Diseases
Collaborator
Steven & Alexandra Cohen Foundation
Collaborator
